Document Detail


Effect of hypertension and hypertension-glucose intolerance on myocardial ischemic injury.
MedLine Citation:
PMID:  14557278     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Systemic hypertension and type 2 diabetes mellitus are major risk factors for myocardial infarction. Yet, glucose intolerance, a prelude stage to type 2 diabetes, is associated with reduced infarct size. Since chronic hypertension adversely affects the myocardium, we tested the hypothesis that the coexistence of systemic hypertension and glucose intolerance reverses the cardioprotection associated with impaired glucose tolerance. Hearts from 9-month-old animals were subjected to a 40-minute occlusion of the left coronary artery followed by 2 hours of reperfusion. Before ischemia, similar values for the four experimental groups were observed for the coronary flow, heart rate, and maximum ventricular pressure. During the course of the ischemia-reperfusion insult, the two hypertensive groups displayed greater reductions in contractility than their normotensive counterparts. Infarct size was lower in the normotensive glucose-intolerant rat than in the normotensive control rat. Surprisingly, the hypertrophied hearts of the hypertensive and hypertensive glucose-intolerant rats displayed reduced infarct size (P<0.05). However, raising the afterload pressure from 100 to 160 cm H2O increased infarct size in the two hypertensive groups. This narrowed the differential between the hypertensive glucose-intolerant (160 cm H2O) and the normotensive control (100 cm H2O) rats. Nonetheless, at the higher afterload pressure, infarct size was less in the hypertensive glucose-intolerant rats than in their hypertensive counterparts. In conclusion, the impairment in contractile function despite the reduction in infarct size underscores the increased susceptibility of the hypertrophied, hypertensive heart to ischemic injury. Furthermore, exacerbation of cell death at elevated afterload pressure indicates the potential benefit of aggressive antihypertensive therapy.
Authors:
Mahmood S Mozaffari; Stephen W Schaffer
Related Documents :
8033508 - Sympathetic restraint of baroreflex control of heart period in normotensive and hyperte...
10409468 - Basal nitric oxide production is impaired in offspring of patients with essential hyper...
1709628 - A comparison of hypertensive and nonhypertensive coronary care patients' cardiovascular...
21590018 - Study of angiotensin ii-induced hypertensive chemotherapy for ovarian cancer in rats.
19949638 - Age is an independent risk factor for the early morning blood pressure surge in patient...
18619118 - Validation of hyperbaric oxygen treatment software for use with monoplace chambers.
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, U.S. Gov't, P.H.S.     Date:  2003-10-13
Journal Detail:
Title:  Hypertension     Volume:  42     ISSN:  1524-4563     ISO Abbreviation:  Hypertension     Publication Date:  2003 Nov 
Date Detail:
Created Date:  2003-11-07     Completed Date:  2003-12-04     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1042-9     Citation Subset:  IM    
Affiliation:
Department of Oral Biology and Maxillofacial Pathology, Medical College of Georgia School of Dentistry, Augusta, Ga 30912-1128, USA. Mmozaffa@mail.mcg.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Glucose Intolerance / complications*
Heart / physiopathology
Hypertension / complications*,  physiopathology
Male
Myocardial Contraction
Myocardial Infarction / etiology
Myocardial Reperfusion Injury / etiology
Organ Culture Techniques
Rats
Rats, Inbred WKY
Grant Support
ID/Acronym/Agency:
HL-63723/HL/NHLBI NIH HHS

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The crystal structures of Klebsiella pneumoniae acetolactate synthase with enzyme-bound cofactor and...
Next Document:  Celiprolol activates eNOS through the PI3K-Akt pathway and inhibits VCAM-1 Via NF-kappaB induced by ...